Akebia Therapeutics (AKBA) Change in Receivables (2013 - 2026)

Akebia Therapeutics (AKBA) has 13 years of Change in Receivables data on file, last reported at $15.7 million in Q1 2026.

• Change in Receivables for Q1 2026 came in at $15.7 million, down 43.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (down 94.59% YoY), and the FY2025 annual result was $14.1 million, up 449.53% from the prior year.
• Change in Receivables grew to $15.7 million in Q1 2026 per AKBA's latest filing, from -$19.1 million in the prior quarter.
• Over five years, Change in Receivables peaked at $27.9 million in Q1 2025 and troughed at -$58.7 million in Q3 2022.
• A 5-year average of $794647.1 and a median of $3.1 million in 2024 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2022 and 2025: Change in Receivables soared 7399.56% in 2022, then tumbled 721.28% in 2025.
• A 5-year view of Change in Receivables shows it stood at $17.0 million in 2022, then decreased by 1.86% to $16.7 million in 2023, then tumbled by 81.59% to $3.1 million in 2024, then plunged by 721.28% to -$19.1 million in 2025, then surged by 182.23% to $15.7 million in 2026.
• Business Quant data shows AKBA's Change in Receivables at $15.7 million in Q1 2026, -$19.1 million in Q4 2025, and -$6.2 million in Q3 2025.